Metrics as of 10/16/2026, 07:48 PM (Berlin time), refresh in progress.
Iovance Biotherapeutics Stock
Iovance Biotherapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Frederick G. Vogt
- Employees
- 975
- Market cap
- $6.2 B
- IPO
- 15/10/2010
Iovance Biotherapeutics, Inc. is a biotechnology company in the healthcare sector headquartered in San Carlos, US. Founded in 2007 and previously known as Lion Biotechnologies, Inc., the firm adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. The company's core business model focuses on discovering…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Iovance Biotherapeutics stock: price history
1D
-7.5%
1W
-6.8%
1M
+38.0%
6M
+252.8%
YTD
+398.9%
1Y
+508.0%
2Y
+45.4%
5Y
-48.8%
10Y
+114.5%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~6% weaker price swings than usual
Iovance Biotherapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Iovance Biotherapeutics is a biotechnology company specializing in the development of immunotherapies to fight cancer cells using the body's own immune system. The company is currently in the clinical development phase and is conducting various Phase 2 studies, including for the active ingredient Lifileucel for the treatment of melanoma, cervical cancer, and head and neck tumors. Additionally, the company maintains strategic collaborations with various medical research centers such as M.D. Anderson Cancer Center and holds partnerships with industry players such as Novartis Pharma AG.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Iovance Biotherapeutics
Analyst assessment of Iovance Biotherapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$13.44
MEDIAN
US$15.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
15
BUY
6
HOLD
0
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 13/10/2026
Iovance Biotherapeutics stock metrics
P/E
-18.66
P/B
8.33
EV/EBITDA
-24.3
RETURN ON EQUITY
-6.4%
NET MARGIN
-47.6%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.0%
FLOAT SHARES
394,257,352
AVG. DAILY VOLUME (30D)
16,701,157
Insider transactions (SEC)
Puri Raj K.
Puri Raj K.
Vogt Frederick G
Vogt Frederick G
BILINSKY IGOR
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.5%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Iovance Biotherapeutics stock
What does Iovance Biotherapeutics do?
Iovance Biotherapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Frederick G. Vogt, the company employs around 975 people.
The IPO was on 15/10/2010; the stock trades on NASDAQ under the ticker IOVA.
What do analysts say about Iovance Biotherapeutics stock?
21 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$13.44, ranging from US$5.00 to US$20.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Iovance Biotherapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Iovance Biotherapeutics pay a dividend?
No, Iovance Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to Iovance Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Iovance Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Iovance Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.